Response to Gultekin et al. regarding SECRAB trial toxicity

Radiother Oncol. 2020 Jun:147:233. doi: 10.1016/j.radonc.2020.01.019. Epub 2020 Feb 8.

Authors

Indrajit N Fernando¹, Sian Lax², Ikhlaaq Ahmed²

Affiliations

¹ Cancer Centre, University Hospitals Birmingham NHS Foundation Trust, United Kingdom. Electronic address: [email protected].
² Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, United Kingdom.

PMID: 32046873
DOI: 10.1016/j.radonc.2020.01.019

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms*
Chemoradiotherapy
Humans

Grants and funding